Pharmaceutical companies will be forced to upgrade their safety database to comply with E2b(R3) or face a major compliance risk. The new standard triggers a lot of changes and the impact and complexities can be difficult to assess for companies. As a consequence, many businesses are not able to accurately lock down the cost and resources for the required upgrade activities. Therefore, Navitas Life Sciences has constructed a “rapid assessment” framework, in order to quickly orient towards what is really necessary and save time and money on the implementation work.
Download this whitepaper to learn Navitas Life Sciences Rapid Assessment 4-step model framework.